Morara Mariachiara1, Ruatta Celeste2, Foschi Federico3, Balducci Nicole1, Ciardella Antonio1. 1. Ophthalmology Unit, S. Orsola-Malpighi Hospital, University of Bologna, Via Pelagio Palagi 9, 40138, Bologna, Italy. 2. University of Bologna, Bologna, Italy. 3. University of Bologna, Bologna, Italy. federico.foschi3@studio.unibo.it.
Abstract
PURPOSE: To report a case of a choroidal metastasis from a non-small-cell lung cancer (NSCLC) with an epidermal growth factor receptor (EGFR) mutation, which responded to Osimertinib, a third-generation EGFR-tyrosine kinase inhibitor (TKI). BACKGROUND: First- and second-generation EGFR-TKis have been widely used for advanced NSCLC patients; however, acquired resistance to these inhibitors, as T790M mutation, could be present in resistant cases. Third-generation EGFR-TKis have emerged as potential therapeutics to overcome this resistance. METHODS: A 54-year-old lady, affected by pulmonary adenocarcinoma with systemic metastases, was diagnosed with choroidal metastasis and since tumor biopsy was positive for the EGFR-T790M mutation, she was included in ASTRIS study, and she received 80 mg tablet of Osimertinib once a day. RESULTS: After a 2-week course of daily therapy with Osimertinib, the improvement of visual acuity was evident with the marked disappearance of visual field defects. We also report a dramatic anatomical reduction of choroidal mass on fundus examination and SD-OCT. These features remained stable at the 4-month follow-up visit. CONCLUSION: This report demonstrates that Osimertinib is effective for choroidal metastasis of NSCLC harboring an EGFR-T790M mutation, which has progressed on or after first- or second-generation EGFR-TKI therapy.
PURPOSE: To report a case of a choroidal metastasis from a non-small-cell lung cancer (NSCLC) with an epidermal growth factor receptor (EGFR) mutation, which responded to Osimertinib, a third-generation EGFR-tyrosine kinase inhibitor (TKI). BACKGROUND: First- and second-generation EGFR-TKis have been widely used for advanced NSCLC patients; however, acquired resistance to these inhibitors, as T790M mutation, could be present in resistant cases. Third-generation EGFR-TKis have emerged as potential therapeutics to overcome this resistance. METHODS: A 54-year-old lady, affected by pulmonary adenocarcinoma with systemic metastases, was diagnosed with choroidal metastasis and since tumor biopsy was positive for the EGFR-T790M mutation, she was included in ASTRIS study, and she received 80 mg tablet of Osimertinib once a day. RESULTS: After a 2-week course of daily therapy with Osimertinib, the improvement of visual acuity was evident with the marked disappearance of visual field defects. We also report a dramatic anatomical reduction of choroidal mass on fundus examination and SD-OCT. These features remained stable at the 4-month follow-up visit. CONCLUSION: This report demonstrates that Osimertinib is effective for choroidal metastasis of NSCLC harboring an EGFR-T790M mutation, which has progressed on or after first- or second-generation EGFR-TKI therapy.
Authors: Akshay Gopinathan Nair; Haresh T Asnani; Vinod C Mehta; Siddharth V Mehta; Rima S Pathak; Amit H Palkar; Indumati Gopinathan Journal: Ocul Oncol Pathol Date: 2016-09-14
Authors: Cecilia M Patino; Rohit Varma; Stanley P Azen; David V Conti; Michael B Nichol; Roberta McKean-Cowdin Journal: Ophthalmology Date: 2011-03-31 Impact factor: 12.079
Authors: Sanket U Shah; Arman Mashayekhi; Carol L Shields; Harpreet S Walia; G Baker Hubbard; Junjun Zhang; Jerry A Shields Journal: Ophthalmology Date: 2013-08-26 Impact factor: 12.079
Authors: Darren A E Cross; Susan E Ashton; Serban Ghiorghiu; Cath Eberlein; Caroline A Nebhan; Paula J Spitzler; Jonathon P Orme; M Raymond V Finlay; Richard A Ward; Martine J Mellor; Gareth Hughes; Amar Rahi; Vivien N Jacobs; Monica Red Brewer; Eiki Ichihara; Jing Sun; Hailing Jin; Peter Ballard; Katherine Al-Kadhimi; Rachel Rowlinson; Teresa Klinowska; Graham H P Richmond; Mireille Cantarini; Dong-Wan Kim; Malcolm R Ranson; William Pao Journal: Cancer Discov Date: 2014-06-03 Impact factor: 39.397